Current Drug Targets

Editor-in-Chief

Francis J. Castellino
(14643 citations)
Dean Emeritus, College of Science,
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
(USA)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 11 Issue: 2, February

Editorial [Hot topic: Anti TNF-α Treatment for Crohns Disease: “Menage A Trois” (Guest Editor: Silvio Danese)]

Volume:11   Issue: 2
Pp: 136-137
Silvio Danese
DOI: 10.2174/138945010790309911
Published on: 01 March, 2012

Efficacy of Anti-TNF in Crohns Disease: How Does it Work?

Volume:11   Issue: 2
Pp: 138-142
Yehuda Chowers and Matthieu Allez
DOI: 10.2174/138945010790309876
Published on: 01 March, 2012

Anti-TNF and Crohns Disease: When Should we Start?

Volume:11   Issue: 2
Pp: 143-147
H. H. Fidder and D. W. Hommes
DOI: 10.2174/138945010790309993
Published on: 01 March, 2012

Anti-TNF and Crohns Disease: When Should We Stop?

Volume:11   Issue: 2
Pp: 148-151
Edouard Louis, Jacques Belaiche and Catherine Reenaers
DOI: 10.2174/138945010790309957
Published on: 01 March, 2012

“How to Manage Loss of Response to Anti-TNF in Crohns Disease?”

Volume:11   Issue: 2
Pp: 152-155
Walter Reinisch
DOI: 10.2174/138945010790309894
Published on: 01 March, 2012

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Volume:11   Issue: 2
Pp: 156-175
Abderrahim Oussalah, Silvio Danese and Laurent Peyrin-Biroulet
DOI: 10.2174/138945010790309939
Published on: 01 March, 2012

Concomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?

Volume:11   Issue: 2
Pp: 176-178
Johannes Meier and Andreas Sturm
DOI: 10.2174/138945010790309948
Published on: 01 March, 2012

Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?

Volume:11   Issue: 2
Pp: 179-186
P. L. Lakatos and P. Miheller
DOI: 10.2174/138945010790309867
Published on: 01 March, 2012

Anti-TNF and Fistulising Perianal Crohns Disease: Use in Clinical Practice

Volume:11   Issue: 2
Pp: 187-197
Leonidas A. Bourikas and Ioannis E. Koutroubakis
DOI: 10.2174/138945010790309966
Published on: 01 March, 2012

How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease

Volume:11   Issue: 2
Pp: 198-218
Emma L. Culver and Simon P.L. Travis
DOI: 10.2174/138945010790310009
Published on: 01 March, 2012

Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows

Volume:11   Issue: 2
Pp: 219-226
D. Sorrentino, A. Paviotti and G. Fiorino
DOI: 10.2174/138945010790309920
Published on: 01 March, 2012

Mucosal Healing and anti TNFs in IBD

Volume:11   Issue: 2
Pp: 227-233
Gert van Assche, Severine Vermeire and Paul Rutgeerts
DOI: 10.2174/138945010790309902
Published on: 01 March, 2012

Anti-TNF Antibody Therapy for Inflammatory Bowel Disease During Pregnancy: A Clinical Review

Volume:11   Issue: 2
Pp: 234-241
Marwa El Mourabet, Sandra El-Hachem, Janet R. Harrison and David G. Binion
DOI: 10.2174/138945010790309885
Published on: 01 March, 2012

Intestinal Fibrosis in Crohns Disease: Medical Treatment or Surgery?

Volume:11   Issue: 2
Pp: 242-248
Antonino Spinelli, Carmen Correale, Hajnalka Szabo and Marco Montorsi
DOI: 10.2174/138945010790309984
Published on: 01 March, 2012

Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?

Volume:11   Issue: 2
Pp: 249-260
Gionata Fiorino, Serena Rovida, Carmen Correale, Alberto Malesci and Silvio Danese
DOI: 10.2174/138945010790309975
Published on: 01 March, 2012